News:

New to the boards? Start with "Welcome! What you need to know as a member of this community"

Main Menu

Seletalisib Phase II Trial published

Started by markt, November 18, 2019, 11:26:30 AM

Previous topic - Next topic
Print
Go Down Pages1
User actions

markt

November 18, 2019, 11:26:30 AM Last Edit: November 18, 2019, 11:33:42 AM by markt
No longer relegated to being studied in murine models...

https://ard.bmj.com/content/78/Suppl_2/1692.2

Seletalisib is a potent, selective oral inhibitor of phosphoinositide-3 kinase delta (PI3Kδ). Preclinical data have shown that the PI3Kδ pathway is upregulated within salivary glands of patients with PSS and contributes to disease pathogenesis.   

https://clinicaltrials.gov/ct2/show/NCT02610543

https://sjogrenssyndromenews.com/2019/01/15/seletalisib-improves-saliva-flow-lowers-inflammation/

It will be interesting to see what happens in lager Phase-III trials...
Print
Go Up Pages1
User actions